牛牛AI助理已提取核心訊息
Biomerica, Inc. reported its financial performance for the quarter ended November 30, 2023, with net sales increasing by 6% to $1,567,000 compared to $1,482,000 in the same period last year. The rise in sales was primarily driven by higher demand for food intolerance products and increased contract manufacturing billings. Cost of sales was $1,242,000, or 79% of net sales, up from 76% in the previous year. The company experienced a net loss of $1,507,000, a slight improvement from a net loss of $1,626,000 in the prior year. Basic and diluted net loss per common share was $(0.09), compared to $(0.12) in the previous year. The company's cash and cash equivalents stood at $7,134,000, with a working capital of $8,443,000. Biomerica's business development included the FDA clearance of its new HP Detect Stool...Show More
Biomerica, Inc. reported its financial performance for the quarter ended November 30, 2023, with net sales increasing by 6% to $1,567,000 compared to $1,482,000 in the same period last year. The rise in sales was primarily driven by higher demand for food intolerance products and increased contract manufacturing billings. Cost of sales was $1,242,000, or 79% of net sales, up from 76% in the previous year. The company experienced a net loss of $1,507,000, a slight improvement from a net loss of $1,626,000 in the prior year. Basic and diluted net loss per common share was $(0.09), compared to $(0.12) in the previous year. The company's cash and cash equivalents stood at $7,134,000, with a working capital of $8,443,000. Biomerica's business development included the FDA clearance of its new HP Detect Stool Antigen ELISA test and the launch of its inFoods IBS product with certain gastroenterology groups. The company is also focusing on expanding its inFoods IBS product and developing new diagnostic products. For future plans, Biomerica is working on increasing sales, reducing expenses, and may seek additional financing through debt and equity financing to meet operating cash requirements and strategic growth objectives beyond the next year.
Biomerica, Inc.公佈了截至2023年11月30日的季度財務業績，淨銷售額從去年同期的148.2萬美元增長了6％，達到15.67萬美元。銷售額的增長主要是由對食物不耐受產品的需求增加和合同製造賬單的增加所推動的。銷售成本爲124.2萬美元，佔淨銷售額的79％，高於去年的76％。該公司的淨虧損爲1,507,000美元，較上一年的淨虧損1,626,000美元略有改善。普通股每股基本虧損和攤薄後的淨虧損爲0.09美元（0.09美元），而去年爲0.12美元。該公司的現金及現金等價物爲7,134,000美元，營運資金爲8,443,000美元。Biomerica的業務發展包括美國食品藥品管理局...展開全部
Biomerica, Inc.公佈了截至2023年11月30日的季度財務業績，淨銷售額從去年同期的148.2萬美元增長了6％，達到15.67萬美元。銷售額的增長主要是由對食物不耐受產品的需求增加和合同製造賬單的增加所推動的。銷售成本爲124.2萬美元，佔淨銷售額的79％，高於去年的76％。該公司的淨虧損爲1,507,000美元，較上一年的淨虧損1,626,000美元略有改善。普通股每股基本虧損和攤薄後的淨虧損爲0.09美元（0.09美元），而去年爲0.12美元。該公司的現金及現金等價物爲7,134,000美元，營運資金爲8,443,000美元。Biomerica的業務發展包括美國食品藥品管理局批准其新的HP Detect Stool 抗原ELISA試驗，以及向某些胃腸病學團體推出InFoods腸易激綜合徵產品。該公司還專注於擴展其InFoods IBS產品和開發新的診斷產品。對於未來的計劃，Biomerica正在努力增加銷售額，減少開支，並可能通過債務和股權融資尋求額外融資，以滿足明年以後的運營現金需求和戰略增長目標。
有用
沒用